Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Othman Al-Sawaf

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Haematologica|March 7, 2024
High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignanciesOthman Al-Sawaf
Blood Advances|June 12, 2026
Remission with residuals, but no cureOthman Al-Sawaf
Acta Haematologica|October 30, 2023
Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic LeukemiaOthman Al-Sawaf
Clinical Advances in Hematology & Oncology : H&O|February 20, 2026
Fixed-duration vs continuous treatment for chronic lymphocytic leukemia in the CLL17 trialOthman Al-Sawaf
Blood|September 11, 2025
ELEVATE-ing clinical trial reporting in CLLFlorian Simon, Othman Al-Sawaf
The Lancet. Oncology|September 13, 2024
Treatment of Richter transformation-immunotherapy to the rescue?Othman Al-Sawaf, Barbara Eichhorst
Blood|December 23, 2021
TP53 mutations in CLL: does frequency matter?Othman Al-Sawaf, Kirsten Fischer
Leukemia & Lymphoma|April 9, 2024
The prognostic significance of genomic complexity in patients with CLLEllinor Goergen, Othman Al-Sawaf
American Journal of Hematology|October 9, 2021
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic proceduresMichael Hallek, Othman Al-Sawaf
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy in patients with Richter transformationKirsten Fischer, Othman Al-Sawaf
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Haematologica|March 7, 2024
High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignanciesOthman Al-Sawaf
Blood Advances|June 12, 2026
Remission with residuals, but no cureOthman Al-Sawaf
Acta Haematologica|October 30, 2023
Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic LeukemiaOthman Al-Sawaf
Clinical Advances in Hematology & Oncology : H&O|February 20, 2026
Fixed-duration vs continuous treatment for chronic lymphocytic leukemia in the CLL17 trialOthman Al-Sawaf
Blood|September 11, 2025
ELEVATE-ing clinical trial reporting in CLLFlorian Simon, Othman Al-Sawaf
The Lancet. Oncology|September 13, 2024
Treatment of Richter transformation-immunotherapy to the rescue?Othman Al-Sawaf, Barbara Eichhorst
Blood|December 23, 2021
TP53 mutations in CLL: does frequency matter?Othman Al-Sawaf, Kirsten Fischer
Leukemia & Lymphoma|April 9, 2024
The prognostic significance of genomic complexity in patients with CLLEllinor Goergen, Othman Al-Sawaf
American Journal of Hematology|October 9, 2021
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic proceduresMichael Hallek, Othman Al-Sawaf
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy in patients with Richter transformationKirsten Fischer, Othman Al-Sawaf
Pageof 8